Abstract
Gene therapy, developing rapidly as a result of advances in molecular biology and the Human Genome Project, is now highlighted as a most hopeful technology of the 21st century. The major goal of gene therapy in diabetes mellitus (DM) is to maintain euglycemia in face of wide variations in dietary intake. Although some obstacles remain to be overcome, the risk-benefit ratio of gene therapy in DM is better than that of lifelong injections of insulin, and islet transplantation, which faces the problems of donor shortage and rejection. This review focuses on the recent advances in gene therapy of insulin-requiring diabetes, with particular emphasis on 1. the gene delivery systems by viral vectors, since most gene therapy approaches for DM involve the use of viral vectors, paying special attention to current efforts to overcome the disadvantages of adenovirus, adenovirus-associated virus and retrovirus vectors and targeting gene delivery for optimal efficiency of gene expression, 2. coupling the synthesis and release of the transgene insulin to serum glucose concentrations, especially with reference to the current promoters controlling at transcriptional level the ectopic insulin expression in autologous hepatocytes, 3. β-cell replacement strategies: engineering of β-cells, especially those derived from pluripotent stem cells, non β-cells, and on a new comer, the K cells. Recent advances in the use of stem cells for potential application in diabetes gene therapy are also discussed.
Keywords: diabetes gene therapy, diabetes mellitus, dm, ddm
Current Gene Therapy
Title: Diabetes Gene Therapy: Potential and Challenges
Volume: 3 Issue: 1
Author(s): Ruian Xu, Hua Li, Tse Lai-yin, Kung Hsiang-fu, Hongyan Lu and Karen S. L. Lam
Affiliation:
Keywords: diabetes gene therapy, diabetes mellitus, dm, ddm
Abstract: Gene therapy, developing rapidly as a result of advances in molecular biology and the Human Genome Project, is now highlighted as a most hopeful technology of the 21st century. The major goal of gene therapy in diabetes mellitus (DM) is to maintain euglycemia in face of wide variations in dietary intake. Although some obstacles remain to be overcome, the risk-benefit ratio of gene therapy in DM is better than that of lifelong injections of insulin, and islet transplantation, which faces the problems of donor shortage and rejection. This review focuses on the recent advances in gene therapy of insulin-requiring diabetes, with particular emphasis on 1. the gene delivery systems by viral vectors, since most gene therapy approaches for DM involve the use of viral vectors, paying special attention to current efforts to overcome the disadvantages of adenovirus, adenovirus-associated virus and retrovirus vectors and targeting gene delivery for optimal efficiency of gene expression, 2. coupling the synthesis and release of the transgene insulin to serum glucose concentrations, especially with reference to the current promoters controlling at transcriptional level the ectopic insulin expression in autologous hepatocytes, 3. β-cell replacement strategies: engineering of β-cells, especially those derived from pluripotent stem cells, non β-cells, and on a new comer, the K cells. Recent advances in the use of stem cells for potential application in diabetes gene therapy are also discussed.
Export Options
About this article
Cite this article as:
Xu Ruian, Li Hua, Lai-yin Tse, Hsiang-fu Kung, Lu Hongyan and Lam S. L. Karen, Diabetes Gene Therapy: Potential and Challenges, Current Gene Therapy 2003; 3 (1) . https://dx.doi.org/10.2174/1566523033347444
DOI https://dx.doi.org/10.2174/1566523033347444 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, further converted to melatonin by ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications
Current Diabetes Reviews High Throughput Metabolomics in Clinical Studies: Review and New Applications to Remote Ischemic Preconditioning
Current Topics in Medicinal Chemistry Role of Polyphenols in Diet and Nutrition-An Updated Review
Current Nutrition & Food Science Platelet Function and Signaling in Diabetes Mellitus
Current Vascular Pharmacology Obstructive Sleep Apnea and Stroke
Current Respiratory Medicine Reviews Current Perspectives on Anti-Aging Interventions
Letters in Drug Design & Discovery Mitochondria: A Novel Therapeutic Target in Diabetic Nephropathy
Current Medicinal Chemistry Nutrition Transition and Obesity Among Teenagers and Young Adults in South Asia
Current Diabetes Reviews Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine
Current Pharmaceutical Design The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins
Current Pharmaceutical Design Interaction Between Genetic Polymorphisms in Renin-Angiotensin System (RAS) and Therapeutic Efficacy of RAS Blockade in IgA Nephropathy
Current Pharmacogenomics Study about How A Sample of Portuguese People Perceive the Health Benefits of Dietary Fibre
Current Nutrition & Food Science Statins: Are They All the Same?
Current Drug Therapy Correction of Murine Diabetic Hyperglycaemia With A Single Systemic Administration of An AAV2/8 Vector Containing A Novel Codon Optimized Human Insulin Gene
Current Gene Therapy A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Association of Hypothyroidism with Body Mass Index, Systolic Blood Pressure and Proteinuria in Diabetic Patients: Does treated Hypothyroidism with Thyroxine Replacement Therapy Prevent Nephropathy/Chronic Renal Disease?
Current Diabetes Reviews The Complex Biology of FOXO
Current Drug Targets